Summary
29.86 -0.25(-0.81%)05/17/2024
Perrigo Company plc (PRGO)
Perrigo Company plc (PRGO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -9.99 | -7.98 | -5.38 | -5.70 | 1.59 | -16.42 | -33.76 | 210.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 30.09 | |
| Open | 32.24 | |
| High | 33.32 | |
| Low | 30.09 | |
| Volume | 3,531,995 | |
| Change | -3.34 | |
| Change % | -9.99 | |
| Avg Volume (20 Days) | 1,193,709 | |
| Volume/Avg Volume (20 Days) Ratio | 2.96 | |
| 52 Week Range | 25.78 - 40.28 | |
| Price vs 52 Week High | -25.30% | |
| Price vs 52 Week Low | 16.72% | |
| Range | -6.67 | |
| Gap Up/Down | -1.21 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,066 | |
| EBIDTA | 610,000,000 | |
| PE Ratio | 3,071.0000 | |
| PEG Ratio | 0.9637 | |
| WallStreet Target Price | 40.50 | |
| Book Value | 34.3870 | |
| Earnings Per Share | 0.0100 | |
| EPS Estimate Current Quarter | 0.2300 | |
| EPS Estimate Next Quarter | 0.5600 | |
| EPS Estimate Current Year | 2.2500 | |
| EPS Estimate Next Year | 2.9700 | |
| Diluted EPS (TTM) | 0.0100 | |
| Revenues | ||
| Profit Marging | -0.0017 | |
| Operating Marging (TTM) | 0.0220 | |
| Return on asset (TTM) | 0.0149 | |
| Return on equity (TTM) | 0.0002 | |
| Revenue TTM | 4,556,000,256 | |
| Revenue per share TTM | 33.5680 | |
| Quarterly Revenue Growth (YOY) | -0.0840 | |
| Quarterly Earnings Growth (YOY) | -0.6360 | |
| Gross Profit (TTM) | 1,455,400,000 | |
| Dividends | ||
| Dividend Share | 1.0950 | |
| Dividend Yield | 0.0359 | |
| Valuations | ||
| Trailing PE | 3,071.0000 | |
| Forward PE | 11.8483 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.8618 | |
| Revenue Enterprise Value | 1.5961 | |
| EBITDA Enterprise Value | 14.1542 | |
| Shares | ||
| Shares Outstanding | 136,320,000 | |
| Shares Float | 135,464,341 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.31 | |
| Institutions (%) | 99.13 | |
05/13 12:56 EST - zacks.com
Understanding Perrigo (PRGO) Reliance on International Revenue
Explore how Perrigo's (PRGO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Understanding Perrigo (PRGO) Reliance on International Revenue
Explore how Perrigo's (PRGO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
05/07 12:26 EST - zacks.com
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
05/07 10:36 EST - zacks.com
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/07 06:31 EST - prnewswire.com
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Transition for the Consumer Self-Care International Business Recently Announced Plan to Divest HRA Rare Diseases Business; Expects to Redeploy Proceeds for Debt Paydown DUBLIN , May 7, 2024 /PRNewswire/ -- First Quarter 2024 Highlights: First quarter net sales of $1.1 billion declined 8.4% versus the prior year quarter. First quarter organic1 net sales decreased 7.0%, due primarily to 1) -4.3 percentage points impact due to lower net sales in infant formula, driven by actions to augment and strengthen the infant formula network, and 2) -3.6 percentage points impact from purposeful SKU prioritization actions to enhance margins as part of the Company's Supply Chain Reinvention Program.
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of Manufacturing Volumes Underway Progressed Blueprint to Build One Perrigo; On Target to Deliver Project Energize Goals; Announced Today in a Separate Press Release the Executive Transition for the Consumer Self-Care International Business Recently Announced Plan to Divest HRA Rare Diseases Business; Expects to Redeploy Proceeds for Debt Paydown DUBLIN , May 7, 2024 /PRNewswire/ -- First Quarter 2024 Highlights: First quarter net sales of $1.1 billion declined 8.4% versus the prior year quarter. First quarter organic1 net sales decreased 7.0%, due primarily to 1) -4.3 percentage points impact due to lower net sales in infant formula, driven by actions to augment and strengthen the infant formula network, and 2) -3.6 percentage points impact from purposeful SKU prioritization actions to enhance margins as part of the Company's Supply Chain Reinvention Program.
05/07 06:28 EST - prnewswire.com
Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business
Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN , May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this year. Roberto Khoury, a consumer self-care veteran with more than 20 years of experience cultivating successful branded consumer products and pan-European brands, will be appointed to lead Perrigo's CSCI segment.
Perrigo Announces Executive Transition for its Consumer Self-Care International (CSCI) Business
Svend Andersen, EVP and President Consumer Self-Care International (CSCI), to Retire Roberto Khoury, a Global Branded Consumer Health Veteran, Appointed to Lead the Business DUBLIN , May 7, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this year. Roberto Khoury, a consumer self-care veteran with more than 20 years of experience cultivating successful branded consumer products and pan-European brands, will be appointed to lead Perrigo's CSCI segment.
05/06 11:41 EST - zacks.com
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
05/06 10:21 EST - zacks.com
Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
05/01 09:42 EST - prnewswire.com
Perrigo Announces Quarterly Dividend
DUBLIN , May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
Perrigo Announces Quarterly Dividend
DUBLIN , May 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
04/30 12:01 EST - zacks.com
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
04/25 06:00 EST - prnewswire.com
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple Expected Net Proceeds to be Redeployed for Debt Repayment Expected Impact From this Proposed Divestment was Included in the Company's Previously Issued 2024 Outlook DUBLIN , April 25, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple Expected Net Proceeds to be Redeployed for Debt Repayment Expected Impact From this Proposed Divestment was Included in the Company's Previously Issued 2024 Outlook DUBLIN , April 25, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
04/23 08:09 EST - prnewswire.com
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
DUBLIN , April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7 th, 2024, and host a conference call beginning at 8:30 A.M. (EDT). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 910565.
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
DUBLIN , April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7 th, 2024, and host a conference call beginning at 8:30 A.M. (EDT). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 910565.
04/09 05:49 EST - seekingalpha.com
Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth
After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in the second half of 2024. Focus on total shareholder returns to be unveiled at the investor day in the fall could be a catalyst for the shares.
Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth
After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in the second half of 2024. Focus on total shareholder returns to be unveiled at the investor day in the fall could be a catalyst for the shares.
04/04 16:59 EST - reuters.com
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors
CVS Caremark, the pharmacy benefit management subsidiary of CVS Health Corp , will add Perrigo's birth control pill to its preventive services oral contraceptives list and make it available at no cost for many plan sponsors, according to a pharmacy update on March 28.
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors
CVS Caremark, the pharmacy benefit management subsidiary of CVS Health Corp , will add Perrigo's birth control pill to its preventive services oral contraceptives list and make it available at no cost for many plan sponsors, according to a pharmacy update on March 28.
03/28 12:36 EST - zacks.com
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
03/04 08:00 EST - prnewswire.com
Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-order from select retailers beginning this week To maximize the impact and accessibility of Opill®, Perrigo has sought to ensure both the affordability and availability of Opill® on shelves across the country and online DUBLIN and GRAND RAPIDS, Mich., March 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Opill® has shipped to major retailers and pharmacies and will be available on shelves nationwide and online later this month.
Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-order from select retailers beginning this week To maximize the impact and accessibility of Opill®, Perrigo has sought to ensure both the affordability and availability of Opill® on shelves across the country and online DUBLIN and GRAND RAPIDS, Mich., March 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Opill® has shipped to major retailers and pharmacies and will be available on shelves nationwide and online later this month.
03/03 10:32 EST - investorplace.com
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
Underdogs stocks carry almost universal appeal. It's one thing to go with the rest of the crowd.
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
Underdogs stocks carry almost universal appeal. It's one thing to go with the rest of the crowd.
02/29 16:21 EST - prnewswire.com
Perrigo to Attend UBS Global Consumer and Retail Conference
DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13 th at 4:00 PM EST. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
Perrigo to Attend UBS Global Consumer and Retail Conference
DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13 th at 4:00 PM EST. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
02/29 12:15 EST - seekingalpha.com
27 Upcoming Dividend Increases Including A Dividend King
A new list of 27 new dividend increases, including King Kimberly-Clark and three other champions.
27 Upcoming Dividend Increases Including A Dividend King
A new list of 27 new dividend increases, including King Kimberly-Clark and three other champions.
02/27 13:35 EST - zacks.com
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations.
02/27 11:45 EST - seekingalpha.com
Perrigo Company Plc (PRGO) Q4 2023 Earnings Call Transcript
Perrigo Company Plc (PRGO) Q4 2023 Earnings Call Transcript
Perrigo Company Plc (PRGO) Q4 2023 Earnings Call Transcript
Perrigo Company Plc (PRGO) Q4 2023 Earnings Call Transcript